[go: up one dir, main page]

PE20120542A1 - Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas - Google Patents

Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas

Info

Publication number
PE20120542A1
PE20120542A1 PE2011001722A PE2011001722A PE20120542A1 PE 20120542 A1 PE20120542 A1 PE 20120542A1 PE 2011001722 A PE2011001722 A PE 2011001722A PE 2011001722 A PE2011001722 A PE 2011001722A PE 20120542 A1 PE20120542 A1 PE 20120542A1
Authority
PE
Peru
Prior art keywords
layer
amlodipine
hydrochlorothiazide
valsartan
solid dosage
Prior art date
Application number
PE2011001722A
Other languages
English (en)
Inventor
Yu Cao
Yatindra Joshi
Ping Li
Madhusudahn Pudipeddi
Alan Edward Royce
Robert Frank Wagner
Jiahao Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38662673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120542(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120542A1 publication Critical patent/PE20120542A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION SOLIDA QUE CONTIENE: A) VALSARTAN EN UNA CANTIDAD 160 A 320MG; B) AMLODIPINA EN FORMA DE BESILATO DE AMLODIPINA EN UNA CANTIDAD DE 5 A 10MG; C) HIDROCLOROTIAZIDA EN UNA CANTIDAD DE 12,5 A 25MG; Y D) ADITIVOS FARMACEUTICAMENTE ACEPTABLES TALES COMO DILUYENTES, DESINTEGRANTES, LUBRICANTES, AGLUTINANTES, ENTRE OTROS. EN DONDE DICHA FORMULACION SOLIDA SE PRESENTA EN FORMA DE TABLETA MONOCAPA O BICAPA, Y CUANDO LA TABLETA ES BICAPA SE TIENE POR EJEMPLO QUE i) EL VALSARTAN E HIDROCLOROTIAZIDA ESTAN EN UNA PRIMERA CAPA Y EL AMLODIPINO EN UNA SEGUNDA CAPA, O ii) EL VALSARTAN ESTA EN UNA PRIMERA CAPA Y EL AMLODIPINO E HIDROCLOROTIAZIDA EN UNA SEGUNDA CAPA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. LA FORMULACION ES UTIL EN EL TRATAMIENTO DE HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, ANGINA, INFARTO DE MIOCARDIO, ARTERIOESCLEROSIS
PE2011001722A 2006-06-27 2007-06-25 Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas PE20120542A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80588306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
PE20120542A1 true PE20120542A1 (es) 2012-05-14

Family

ID=38662673

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001722A PE20120542A1 (es) 2006-06-27 2007-06-25 Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
PE2007000810A PE20080991A1 (es) 2006-06-27 2007-06-25 Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000810A PE20080991A1 (es) 2006-06-27 2007-06-25 Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas

Country Status (22)

Country Link
US (2) US20100003321A1 (es)
EP (1) EP2037893A2 (es)
JP (1) JP2009542709A (es)
KR (1) KR20090021191A (es)
CN (2) CN103169711A (es)
AR (1) AR061627A1 (es)
AU (1) AU2007265138A1 (es)
BR (1) BRPI0713785A2 (es)
CA (1) CA2654986A1 (es)
CL (1) CL2007001870A1 (es)
EC (1) ECSP088987A (es)
IL (1) IL195797A0 (es)
MA (1) MA30529B1 (es)
MX (1) MX2008016532A (es)
NO (1) NO20090314L (es)
NZ (1) NZ573295A (es)
PE (2) PE20120542A1 (es)
RU (1) RU2449786C2 (es)
TN (1) TNSN08538A1 (es)
TW (1) TW200808379A (es)
WO (1) WO2008002905A2 (es)
ZA (1) ZA200810053B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AU2010212865A1 (en) 2009-02-13 2011-07-21 Boehringer Ingelheim International Gmbh SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2011001440A1 (en) * 2009-07-03 2011-01-06 Hetero Research Foundation Pharmaceutical compositions of valsartan
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CN102091069A (zh) * 2009-12-11 2011-06-15 浙江华海药业股份有限公司 缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101829111B (zh) * 2010-05-23 2014-12-17 浙江华海药业股份有限公司 含有缬沙坦的固体制剂及其制备方法
CN102716132B (zh) * 2011-03-29 2015-09-30 石药集团中奇制药技术（石家庄）有限公司 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
AU2012360935A1 (en) * 2011-12-26 2014-07-17 Novartis Ag Tablets and dry-coated agents
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102614190A (zh) * 2012-04-17 2012-08-01 北京哈三联科技股份有限公司 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
MX358211B (es) 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
CN103655580B (zh) * 2012-08-28 2017-12-01 海南中济医药科技有限公司 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法
WO2014058047A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
CN102846625A (zh) * 2012-10-18 2013-01-02 海口华仕联医药科技有限公司 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
US20200316029A1 (en) * 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
US20180125813A1 (en) 2016-11-10 2018-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES3038007T3 (en) 2017-02-27 2025-10-08 Idorsia Pharmaceuticals Ltd Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
BR112020010831A2 (pt) 2017-11-30 2020-11-10 Idorsia Pharmaceuticals Ltd composição farmacêutica, aprocitentan, e, método
WO2022132067A1 (en) * 2020-12-18 2022-06-23 Santa Farma Ilac Sanayii A.S. Stable bilayer tablet compositions
CN113171352A (zh) * 2021-04-15 2021-07-27 海南锦瑞制药有限公司 一种沙坦类降压复方制剂的制备方法
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
SI1467712T2 (sl) * 2002-01-16 2011-11-30 Boehringer Ingelheim Pharma Postopek za pripravo dvoplastne farmacevtske tablete ki obsega telmisartan in hidroklorotiazid
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100580168B1 (ko) 2003-03-21 2006-05-16 삼성전자주식회사 다중 홈 에이전트 제어장치 및 방법
WO2005070462A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
US20080241239A1 (en) 2004-05-21 2008-10-02 Lawrence Solomon Pharmaceutical Tablets Having a Separation Mark Positioned on the Side of Said Tablets
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
CN100389830C (zh) * 2005-05-08 2008-05-28 广州市施柏医药科技有限公司 一种治疗高血压的药物组合物

Also Published As

Publication number Publication date
TNSN08538A1 (en) 2010-04-14
CL2007001870A1 (es) 2008-06-13
ZA200810053B (en) 2009-11-25
US20100003321A1 (en) 2010-01-07
MA30529B1 (fr) 2009-06-01
NO20090314L (no) 2009-01-26
US8475839B2 (en) 2013-07-02
RU2009102273A (ru) 2010-08-10
MX2008016532A (es) 2009-01-19
RU2449786C2 (ru) 2012-05-10
KR20090021191A (ko) 2009-02-27
AU2007265138A1 (en) 2008-01-03
CA2654986A1 (en) 2008-01-03
WO2008002905A2 (en) 2008-01-03
EP2037893A2 (en) 2009-03-25
WO2008002905A3 (en) 2008-12-11
ECSP088987A (es) 2009-01-30
CN103169711A (zh) 2013-06-26
JP2009542709A (ja) 2009-12-03
NZ573295A (en) 2012-01-12
PE20080991A1 (es) 2008-09-05
AR061627A1 (es) 2008-09-10
BRPI0713785A2 (pt) 2012-10-30
CN101478956A (zh) 2009-07-08
IL195797A0 (en) 2009-09-01
US20120164218A1 (en) 2012-06-28
TW200808379A (en) 2008-02-16
CN101478956B (zh) 2013-03-20
HK1133818A1 (en) 2010-04-09

Similar Documents

Publication Publication Date Title
PE20120542A1 (es) Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
AR123409A2 (es) Composiciones terapéuticas
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2008001446A1 (es) Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico.
CY1115087T1 (el) Παραγωγα αμινο-πυριδινων ως αγωνιστες των υποδοχεων s1p1/edg1
AR066168A1 (es) Formulaciones galenicas de compuestos organicos
CL2015000120A1 (es) Compuestos derivados de acidos 5-aminotetrahidroquinolin-2-carboxilicos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de hipertension pulmonar, insuficiencia cardiaca, angina de pecho, hipertension, enfermedades tromboembolicas, enfermedades fibroticas, isquemias, entre otras.
UY29405A1 (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la continen.
CO6430463A2 (es) Activadores de guanilato ciclasa solubles
CL2013002902A1 (es) Compuestos del acido propanoico derivados dek 3-(acetil-amino-fenil)-fenil; procedimiento de preparacion de los compuestos; composicion farmaceutica; y uso como activadores de la forma libre de hemo de la guanilato ciclasa soluble, en el tratamiento de insuficiencia cardiaca, angina de pecho, hipertension, afecciones tromboembolicas, isquemias, entre otras.
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
NO20052734L (no) Tablett med flere lag, inneholdende pravastatin og aspirin, og fremgangsmate
CL2010001123A1 (es) Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07).
MX2012004673A (es) Composiciones farmaceuticas de combinaciones de inhibidores de dipeptidil peptidasa 4 con pioglitazona.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR028994A1 (es) Compuesto de sal mutua de amlodipino y atorvastatina y composiciones que la contienen
CR11398A (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
MX2007004197A (es) Antagonistas del receptor de trombina.
MX2021009755A (es) Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos.
WO2013062902A3 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin
CL2012002341A1 (es) Composición farmacéutica sólida oral que comprende ramipril y besilato de amlodipino; procedimiento de preparación; uso en el tratamiento de hipertensión arterial y prevención de infarto de miocardio, trastornos cerebrovasculares y cardíacos e insuficiencia renal.
CL2011001496A1 (es) Compuestos derivados de 2-piridin-2-il-pirazol-3(2h)-ona, activadores de hif; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades cardiacas perifericas de origen isquemico, entre otras.

Legal Events

Date Code Title Description
FD Application declared void or lapsed